Fatty Acid Oxidation Disorders (FAODs) Global Market Report 2025
상품코드:1730856
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 175 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
지방산 대사장애(FAOD) 시장 규모는 향후 수년간 강력한 성장이 예상될 예정입니다. 예측 기간 동안의 성장은 지속 가능한 바이오 제품에 대한 수요 증가, 개인 맞춤형 의약품의 채택 증가, FAOD의 조기 진단, 연구 개발 자금 증가, 장기적인 성과 향상에 대한 집중력 강화에 기인할 수 있습니다.
유전자 치료에 대한 수요 증가는 향후 지방산 대사장애(FAOD) 시장의 확대를 견인할 것으로 예측됩니다. 유전자 치료에 대한 수요가 증가하는 이유는 근본적인 유전적 원인을 표적으로 삼아 유전 질환, 암, 희귀 질환을 치료할 수 있는 잠재력 때문입니다. 에너지 생산을 강화하고 질병의 합병증을 예방하는 기능적 유전자를 제공함으로써 지방산 대사장애로 인한 대사 부전에 대처하는 것을 목적으로 하고 있습니다. 예를 들어, 2024년 4월 미국 유전자 및 세포 치료학회는 4분기에 3상 임상시험 중인 유전자 치료제의 수가 10% 증가하여 2022년 3분기 이후 처음으로 분기별 성장률을 기록했다고 보고했습니다.
지방산 대사장애(FAOD) 시장의 기업은 FAOD 환자의 대사 제어 및 치료 성적을 개선하기 위해 퍼옥시좀 증식 인자 활성화 수용체 델타(PPARδ) 작용제와 같은 혁신적인 솔루션을 개발하고 있습니다. PPARδ 작용제는 지질 대사, 염증 및 에너지 균형을 조절하는 데 중요한 역할을 하는 PPARδ 수용체를 활성화합니다. 예를 들어, 2023년 1월, Reneo Pharmaceuticals는 장쇄 지방산 산화 장애(LC-FAOD)와 관련된 유전자형인 장쇄 3-하이드록시아실--코아 탈수소효소(LCHAD) 결핍을 표적으로 하는 임상시험용 약물인 Mavodelpar(REN001)에 대해 미국 식품의약국(FDA)의 신속 심사 지정을 받았습니다. 마보델파는 PPARδ를 활성화하여 미토콘드리아 기능을 개선하고 에너지 대사를 증진하며 LC-FAOD와 관련된 증상을 완화하는 것을 목표로 합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 지방산 대사장애(FAOD) 시장의 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인 및 억제요인)
최종 이용 산업의 분석
세계의 지방산 대사장애(FAOD) 시장 : 성장률 분석
세계의 지방산 대사장애(FAOD) 시장 실적 : 규모와 성장(2019-2024년)
세계의 지방산 대사장애(FAOD) 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 지방산 대사장애(FAOD) 전체 시장(TAM)
제6장 시장 세분화
세계의 지방산 대사장애(FAOD) 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
장쇄
단쇄
세계의 지방산 대사장애(FAOD) 시장 : 약제 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
레보카르니틴
포도당
리보플라빈
기타
세계의 지방산 대사장애(FAOD) 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
경구
정맥 내
세계의 지방산 대사장애(FAOD) 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원 약국
소매 약국
약국
온라인 스토어
세계의 지방산산화장애(FAOD) 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원
클리닉
제약회사
세계의 지방산 대사장애(FAOD) 시장 : 장쇄 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
극장쇄 아실-코아 탈수소효소 결핍(VLCAD)
장쇄 3-하이드록시아실-코아 탈수소효소 결핍(LCHAD)
삼기능성 단백질 결핍(TFP)
카르니틴 팔미토일 트랜스퍼라제 II 결핍(CPT II)
세계의 지방산 대사장애(FAOD) 시장 : 단쇄 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
중쇄 아실-코아 탈수소효소 결핍(MCAD)
단쇄 아실-코아 탈수소효소 결핍(SCAD)
카르니틴 흡수 결함(CUD)
제7장 지역별/국가별 분석
세계의 지방산 대사장애(FAOD) 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 지방산 대사장애(FAOD) 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
지방산 대사장애(FAOD) 시장 : 경쟁 구도
지방산 대사장애(FAOD) 시장 : 기업 프로파일
BASF SE : 개요, 제품 및 서비스, 전략 및 재무 분석
Thermo Fisher Scientific Inc : 개요, 제품 및 서비스, 전략 및 재무 분석
Takeda Pharmaceutical Company Limited : 개요, 제품 및 서비스, 전략 및 재무 분석
Baxter International Inc : 개요, 제품 및 서비스, 전략 및 재무 분석
Koninklijke DSM NV : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Ingredion Incorporated
Lonza Group Ltd
Roquette Freres SA
Dr Reddy's Laboratories Limited
Tate & Lyle PLC
ANI Pharmaceuticals Inc
Ultragenyx Pharmaceutical Inc
Gulshan Polyols Limited
Hubei Guangji Pharmaceutical Co Ltd
Omega Laboratories Limited
Actiza Pharmaceutical Private Limited
Allmpus Laboratories Private Limited
Reneo Pharmaceuticals Inc
Greenwell Lifesciences
NB Group Co Ltd
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
지방산 대사장애(FAOD) 시장(2029년) : 새로운 기회를 제공하는 국가
지방산 대사장애(FAOD) 시장(2029년) : 새로운 기회를 제공하는 부문
지방산 대사장애(FAOD) 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
KTH
영문 목차
영문목차
Fatty acid oxidation disorders (FAODs) are a group of rare inherited metabolic conditions that disrupt the body's ability to convert fats into energy due to a lack or malfunction of specific enzymes necessary for fatty acid breakdown. As a result, fatty acids accumulate in the body, leading to severe energy shortages, hypoglycemia, muscle weakness, and potential organ damage, especially during times of fasting or illness.
The primary types of fatty acid oxidation disorders are long-chain and short-chain disorders. Long-chain fatty acid oxidation disorders (LC-FAODs) are conditions where the body cannot properly metabolize long-chain fatty acids for energy, causing energy deficiencies and metabolic disturbances. Treatment options include medications such as levocarnitine, dextrose, riboflavin, and others, which can be administered through oral or intravenous routes. These medications are distributed through hospital pharmacies, retail pharmacies, drugstores, and online platforms, with end users including hospitals, clinics, and pharmaceutical companies.
The fatty acid oxidation disorders (FAODs) market research report is one of a series of new reports from The Business Research Company that provides fatty acid oxidation disorders (FAODs) market statistics, including the fatty acid oxidation disorders (FAODs) industry global market size, regional shares, competitors with the fatty acid oxidation disorders (FAODs) market share, detailed fatty acid oxidation disorders (FAODs) market segments, market trends, and opportunities, and any further data you may need to thrive in the fatty acid oxidation disorders (FAODs) industry. This fatty acid oxidation disorders (FAODs) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The fatty acid oxidation disorders (FAODs) market size has grown strongly in recent years. It will grow from $9.55 billion in 2024 to $10.33 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth during the historic period can be attributed to factors such as greater awareness, a rise in the prevalence of rare and genetic disorders, an increasing number of product approvals, enhanced government initiatives, and a growing demand for orphan drugs.
The fatty acid oxidation disorders (FAODs) market size is expected to see strong growth in the next few years. It will grow to $13.99 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth during the forecast period can be attributed to the growing demand for sustainable bio-products, the increasing adoption of personalized medicine, earlier diagnosis of FAODs, rising funding for research and development, and a stronger focus on enhancing long-term outcomes. Key trends in the forecast period include the integration of telehealth services, the use of artificial intelligence in diagnostics and drug discovery, advancements in genetic testing, technological innovations, and a shift towards patient-centric care models.
The growing demand for gene therapy is anticipated to drive the expansion of the fatty acid oxidation disorders (FAODs) market in the future. Gene therapy involves modifying or replacing defective genes to treat or prevent diseases. The rising demand for gene therapy is due to its potential to treat genetic disorders, cancer, and rare diseases by targeting the underlying genetic causes. This has led to significant investments and advancements in biotechnology. Gene therapy aims to address metabolic deficiencies caused by fatty acid oxidation disorders by delivering functional genes to restore enzymatic activity, enhance energy production, and prevent disease complications. For example, in April 2024, the American Society of Gene & Cell Therapy reported a 10% increase in the number of gene therapies in Phase III clinical trials in the fourth quarter, marking the first quarterly growth of this kind since the third quarter of 2022. As a result, the rising demand for gene therapy is fueling the growth of the FAODs market.
Companies in the FAODs market are developing innovative solutions such as peroxisome proliferator-activated receptor delta (PPARδ) agonists to improve metabolic control and treatment outcomes for patients with FAODs. A PPARδ agonist activates the PPARδ receptor, which plays a key role in regulating lipid metabolism, inflammation, and energy balance. This approach may offer therapeutic benefits for metabolic disorders and cardiovascular diseases. For instance, in January 2023, Reneo Pharmaceuticals Inc. received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its investigational drug, Mavodelpar (REN001), which targets long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency, a genotype linked to long-chain fatty acid oxidation disorder (LC-FAOD). By activating PPARδ, Mavodelpar aims to improve mitochondrial function, enhance energy metabolism, and alleviate symptoms related to LC-FAOD.
In October 2024, OnKure Therapeutics Inc., a US-based pharmaceutical company, merged with Reneo Pharmaceuticals Inc. in an undisclosed deal. The merger combines OnKure's expertise in precision oncology with Reneo's resources to accelerate the development of targeted therapies for oncogenic PI3Ka mutations, specifically using mutant-selective PI3Ka inhibitors. Reneo Pharmaceuticals specializes in developing treatments for fatty acid oxidation disorders.
Major players in the fatty acid oxidation disorders (FAODs) market are BASF SE, Thermo Fisher Scientific Inc, Takeda Pharmaceutical Company Limited, Baxter International Inc, Koninklijke DSM NV, Ingredion Incorporated, Lonza Group Ltd, Roquette Freres SA, Dr Reddy's Laboratories Limited, Tate & Lyle PLC, ANI Pharmaceuticals Inc, Ultragenyx Pharmaceutical Inc, Gulshan Polyols Limited, Hubei Guangji Pharmaceutical Co Ltd, Omega Laboratories Limited, Actiza Pharmaceutical Private Limited, Allmpus Laboratories Private Limited, Reneo Pharmaceuticals Inc, Greenwell Lifesciences, and NB Group Co Ltd.
Asia-Pacific was the largest region in the fatty acid oxidation disorders (FAODs) market in 2024. The regions covered in fatty acid oxidation disorders (FAODs) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the fatty acid oxidation disorders (FAODs) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The fatty acid oxidation disorders (FAODs) market consists of revenues earned by entities by providing services such as newborn screening and genetic testing, nutritional therapy, remote monitoring, and patient support. The market value includes the value of related goods sold by the service provider or included within the service offering. The fatty acid oxidation disorders (FAODs) market also includes sales of medical foods and supplements, diagnostic and genetic testing kits, and nutritional supplements. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Fatty Acid Oxidation Disorders (FAODs) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on fatty acid oxidation disorders (faods) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for fatty acid oxidation disorders (faods) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The fatty acid oxidation disorders (faods) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Long Chain; Short Chain
2) By Drug Type: Levocarnitine; Dextrose; Riboflavin; Other Drug Types
3) By Route of Administration: Oral; Intravenous
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Drug Stores; Online Stores
5) By End User: Hospitals; Clinics; Pharmaceutical Companies
Subsegments:
1) By Long Chain: Very Long-Chain Acyl-CoA Dehydrogenase Deficiency (VLCAD); Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency (LCHAD); Trifunctional Protein Deficiency (TFP); Carnitine Palmitoyltransferase II Deficiency (CPT II)
2) By Short Chain: Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCAD); Short-Chain Acyl-CoA Dehydrogenase Deficiency (SCAD); Carnitine Uptake Defect (CUD)
Companies Mentioned: BASF SE; Thermo Fisher Scientific Inc; Takeda Pharmaceutical Company Limited; Baxter International Inc; Koninklijke DSM NV
3. Fatty Acid Oxidation Disorders (FAODs) Market Trends And Strategies
4. Fatty Acid Oxidation Disorders (FAODs) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Fatty Acid Oxidation Disorders (FAODs) Growth Analysis And Strategic Analysis Framework
5.1. Global Fatty Acid Oxidation Disorders (FAODs) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
6.1. Global Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Long Chain
Short Chain
6.2. Global Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Levocarnitine
Dextrose
Riboflavin
Other Drug Types
6.3. Global Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Intravenous
6.4. Global Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Stores
6.5. Global Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Pharmaceutical Companies
6.6. Global Fatty Acid Oxidation Disorders (FAODs) Market, Sub-Segmentation Of Long Chain, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Very Long-Chain Acyl-CoA Dehydrogenase Deficiency (VLCAD)
Carnitine Palmitoyltransferase II Deficiency (CPT II)
6.7. Global Fatty Acid Oxidation Disorders (FAODs) Market, Sub-Segmentation Of Short Chain, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Fatty Acid Oxidation Disorders (FAODs) Market
9.1. China Fatty Acid Oxidation Disorders (FAODs) Market Overview
9.2. China Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Fatty Acid Oxidation Disorders (FAODs) Market
10.1. India Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Fatty Acid Oxidation Disorders (FAODs) Market
11.1. Japan Fatty Acid Oxidation Disorders (FAODs) Market Overview
11.2. Japan Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Fatty Acid Oxidation Disorders (FAODs) Market
12.1. Australia Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Fatty Acid Oxidation Disorders (FAODs) Market
13.1. Indonesia Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Fatty Acid Oxidation Disorders (FAODs) Market
14.1. South Korea Fatty Acid Oxidation Disorders (FAODs) Market Overview
14.2. South Korea Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Fatty Acid Oxidation Disorders (FAODs) Market
15.1. Western Europe Fatty Acid Oxidation Disorders (FAODs) Market Overview
15.2. Western Europe Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Fatty Acid Oxidation Disorders (FAODs) Market
16.1. UK Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.1. Spain Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Fatty Acid Oxidation Disorders (FAODs) Market
21.1. Eastern Europe Fatty Acid Oxidation Disorders (FAODs) Market Overview
21.2. Eastern Europe Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Fatty Acid Oxidation Disorders (FAODs) Market
22.1. Russia Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Fatty Acid Oxidation Disorders (FAODs) Market
23.1. North America Fatty Acid Oxidation Disorders (FAODs) Market Overview
23.2. North America Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Fatty Acid Oxidation Disorders (FAODs) Market
24.1. USA Fatty Acid Oxidation Disorders (FAODs) Market Overview
24.2. USA Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Fatty Acid Oxidation Disorders (FAODs) Market
26.1. South America Fatty Acid Oxidation Disorders (FAODs) Market Overview
26.2. South America Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Fatty Acid Oxidation Disorders (FAODs) Market
27.1. Brazil Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Fatty Acid Oxidation Disorders (FAODs) Market
28.1. Middle East Fatty Acid Oxidation Disorders (FAODs) Market Overview
28.2. Middle East Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Fatty Acid Oxidation Disorders (FAODs) Market
29.1. Africa Fatty Acid Oxidation Disorders (FAODs) Market Overview
29.2. Africa Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Fatty Acid Oxidation Disorders (FAODs) Market Competitive Landscape And Company Profiles
